Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study

Table 3 Overall prognosis after radiotherapy in post-BCS patients

	Total (N)	Event (N)	Incidence rate (%)	Reduction rate (%)	aHR	95% CI	p value
LR				66	0.33	0.25–0.44	< 0.0001
No RT	6472	202	3.1
RT	6565	69	1.1
Total	13,164	271	2.1
RR				72	0.29	0.19–0.43	< 0.0001
No RT	6538	105	1.6
RT	6574	30	0.5
Total	13,112	135	1.0
DM				19	0.81	0.66–0.99	0.044
No RT	6520	218	3.3
RT	6561	177	2.7
Total	13,081	395	3.0
DFS				48	0.50	0.43–0.58	< 0.0001
No RT	6375	509	8.0
RT	6537	270	4.1
Total	12,912	779	6.0
OS				46	0.51	0.45–0.58	< 0.0001
No RT	6582	715	10.9
RT	6582	387	5.9
Total	13,164	1102	8.4

RT radiotherapy, LR local recurrence, RR regional recurrence, DM distant metastasis, DFS disease-free survival, OS overall survival; aHR adjusted hazard ratio, 95% CI 95% confidence interval
aHR was obtained from multivariate analysis which was based on Fine and Gray competing risks proportional hazards regression model by adjusting age, molecular subtypes of breast tumor, clinical and pathological stage, comorbidities, chemotherapy, hormone therapy, target therapy, anti-cancer agents, and socioeconomic status

ISSN: 1465-542X